Description
+ Include: 33 videos + 30 pdfs, size: 10.5 GB
+ Target Audience: hematologist, physicians, researchers, fellows, advanced practice providers, who provide care for patients undergoing HCT
+ Sample video: contact me for sample video
+ Information:
Friday, October 11, 2019, 7:00 AM – Saturday, October 12, 2019, 1:00 PM EST, Zuckerman Research Center, 417 East 68th Street, New York , NY
Today, more than 10,000 hematopoietic cell transplantations (HCTs) are performed yearly in the United States as treatment for more than 70 life threatening illnesses including cancers, genetic disorders, and other diseases. Also, given the shift toward cellular therapies in the field of HCT, the number of patients treated with these novel biologic agents is rapidly increasing.
Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, this symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.
The target audience for this symposium includes physicians, researchers, fellows, advanced practice providers, nurses, pharmacists, data managers and other healthcare professionals who provide care for patients undergoing HCT and cellular therapies.
We are pleased to offer a live simulcast option for the 2nd International Symposium on Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy. CME credit is offered for the live simulcast and active participation is required throughout the course. We do hope you will attend in person but understand that can sometimes be a challenge so we are happy to offer the live simulcast as an option. Registration for the simulcast is required; to register, please select the “Live Simulcast” option during course registration.
The 2nd International Symposium on Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy invites the submission of abstracts. Abstracts for the poster session will be selected on the basis of scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and/or clinical research in progress will be accepted. Top awarded abstracts will receive a travel grant tied to attending this symposium. To submit an abstract, please select the ‘Abstract’ button above.
- Understand the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.
- Identify best practices to prevent and treat toxicities and symptom burden after HCT and cellular therapy to improve the patient experience and reduce non-relapse mortality.
- Understand how to approach prevention and treatment of toxicities and symptom burden in unique HCT and cellular therapy patient populations.
+ Topics:
Accelerated Functional Aging and Sarcopenia After HCT.mp4
Accelerated Functional Aging and Sarcopenia After HCT.pdf
Are CAR T Cells and Novel Cellular Therapies Cost-effective..mp4
Are CAR T Cells and Novel Cellular Therapies Cost-effective..pdf
Association of Patient and Donor Clonal Hematopoiesis with HCT Toxicities.mp4
Association of Patient and Donor Clonal Hematopoiesis with HCT Toxicities.pdf
Association of the Pulmonary Virioma and Post-HCT Pulmonary Toxicities.mp4
Association of the Pulmonary Virioma and Post-HCT Pulmonary Toxicities.pdf
Choosing Wisely in HCT and Its Applicability to Novel Cellular Therapies.mp4
Choosing Wisely in HCT and Its Applicability to Novel Cellular Therapies.pdf
Chronic Disease Burden in Survivors of Childhood HCT.mp4
Chronic Disease Burden in Survivors of Childhood HCT.pdf
Emerging Evidence on the Pathobiology and Biomarkers of Regimen-Related Mucosal Injury.mp4
Emerging Evidence on the Pathobiology and Biomarkers of Regimen-Related Mucosal Injury.pdf
EN v. PN – Nutritional Supplementation Early After HCT – Enteral or Parenteral.mp4
EN v. PN – Nutritional Supplementation Early After HCT – Enteral or Parenteral.pdf
End-of-Life Care in HCT- What Do HCT Physicians Think About Palliative Care..mp4
End-of-Life Care in HCT- What Do HCT Physicians Think About Palliative Care..pdf
GI and Hepatobiliary Complications of HCT.mp4
GI and Hepatobiliary Complications of HCT.pdf
Harmonizing Conditioning Regimens – How PK PD Impacts Toxicities and Outcomes.mp4
Harmonizing Conditioning Regimens – How PK PD Impacts Toxicities and Outcomes.pdf
Harmonizing VOD SOS Diagnosis and Classification.mp4
Harmonizing VOD SOS Diagnosis and Classification.pdf
Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy.mp4
Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy.pdf
Human Microbiome in Hematopoiesis and Immune Recovery After HCT and Cellular Therapies.mp4
Human Microbiome in Hematopoiesis and Immune Recovery After HCT and Cellular Therapies.pdf
Importance of Standardizing Cause-specific Death Adjudication After HCT and Cellular Therapies.mp4
Importance of Standardizing Cause-specific Death Adjudication After HCT and Cellular Therapies.pdf
Incorporating Biomarkers of Non-GVHD Toxicity in Clinical Trial Design.mp4
Incorporating Biomarkers of Non-GVHD Toxicity in Clinical Trial Design.pdf
Lunch Breakout (105)- Endothelial Activation and Stress Index (EASIX) results predicts outcomes in unmodified and CD34-selected grafts.mp4
Lunch Breakout (105)- Endothelial Activation and Stress Index (EASIX) results predicts outcomes in unmodified and CD34-selected grafts.pdf
Lunch Breakout (136)- Harnessing Telemedicine Potential in HCT and Cellular Therapies.mp4
Lunch Breakout (136)- Harnessing Telemedicine Potential in HCT and Cellular Therapies.pdf
Lunch Breakout (136)t- HCT Telehealth Care- Can you Hear Me Now..mp4
Lunch Breakout (136)t- HCT Telehealth Care- Can you Hear Me Now.pdf
Mechanisms of Gastrointestinal Injury in HCT – Learning from IBD.mp4
Mechanisms of Gastrointestinal Injury in HCT – Learning from IBD.pdf
Novel Biomarkers of Acute and Chronic Renal Injury After HCT and Cellular Therapies.mp4
Novel Biomarkers of Acute and Chronic Renal Injury After HCT and Cellular Therapies.pdf
Patient-Reported Outcomes and Symptom Burden After CAR T Cell Therapy.mp4
Patient-Reported Outcomes and Symptom Burden After CAR T Cell Therapy.pdf
Preventing All-Cause Death after HCT – What Should be our Focus when Designing Trials.mp4
Preventing All-Cause Death after HCT – What Should be our Focus when Designing Trials.pdf
Q&A with Speakers I.mp4
Q&A with Speakers II.mp4
Q&A with Speakers III.mp4
Q&A with Speakers Networking Reception & Poster.mp4
Q&A with Speakers.mp4
Strategies to Improve Immune Reconstitution After HCT and Novel Cellular Therapie.mp4
Strategies to Improve Immune Reconstitution After HCT and Novel Cellular Therapie.pdf
The Injured Endothelium in HCT Toxicities.pdf
The Injured Endothelium in HCT ToxicitiesThe Injured Endothelium in HCT Toxicities.mp4
The Short and Long-Term Costs of Critical Illness After HCT and Cellular Therapies.mp4
The Short and Long-Term Costs of Critical Illness After HCT and Cellular Therapies.pdf
Toxicities and Outcomes in the Geriatric Patient After HCT and Cellular Therapies.mp4
Toxicities and Outcomes in the Geriatric Patient After HCT and Cellular Therapies.pdf
Toxicities_2019_Brochure2.pdf
Virus specific T cells to Mitigate Infectious Complications After HCT.mp4
Virus specific T cells to Mitigate Infectious Complications After HCT.pdf
Welcome, Opening Remarks and Conference Overview.pdf
Reviews
There are no reviews yet.